News & Publications

ViVac announced the expansion of its leadership and scientific advisory network , adding world-class expertise in synthetic biology, immuno-oncology, and nanomedicine to support its mission of transforming cancer treatment through programmable RNA therapeutics. The additions build upon the company’s foundation in the Synthetic Biology Lab of Prof. Lior Nissim  and the Membrane & Liposome Lab of Prof. Chezy Barenholz , inventor of Doxil®  and one of Stanford’s top 2% most-cite

ViVac has achieved a major scientific milestone with confirmed in vivo RNA expression  and tumor-targeted delivery  using its proprietary synthetic RNA–Lipid Nanoparticle (LNP) platform. The data validate the company’s vision of combining viral potency with RNA-level safety to create a new generation of localized cancer immunotherapies. The results demonstrate that ViVac’s engineered RNA replicons can safely express within tumor cells while remaining self-limiting — a breakth

ViVac announced the appointment of Keren Leshem as Chief Executive Officer, marking a significant milestone in the company’s evolution from research-driven startup to emerging leader in RNA-based cancer immunotherapy. Leshem, a World Economic Forum Technology Pioneer CEO , has been recognized by Forbes and Entrepreneur as one of the most influential voices in biotechnology. She brings over two decades of experience building and scaling clinical-stage life science companies